SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (5094)12/10/2001 3:27:15 PM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
And in the comparative valuation arena, I notice that AMGN's market cap ($68.5 billion) comfortably exceeds that of GM's ($28 billion) and Ford's ($30.5 billion) combined. In fact, I think you could throw in the major airlines with the exception of Southwest as well, and AMGN still comes out ahead of the combination.

I find that somewhat disturbing.

Peter



To: Biomaven who wrote (5094)12/11/2001 10:44:32 AM
From: Extra Pale  Read Replies (1) | Respond to of 52153
 
Peter, how does celg's Revimid stack up to LDP-341? seems like we may have competing blockbusters in a few years. If one compound is clearly superior - wouldn't that have a major impact on the valuation of both companies?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News